Sanofi produced considerably better results in the third quarter than its record for the first nine months, opening the possibility that loss of patent protection on certain drugs will be less of a drag on its accounts going into the future.
Sanofi produced considerably better results in the third quarter than its record for the first nine months, opening the possibility that loss of patent protection on certain drugs will be less of a drag on its accounts going into the future.